HHS releases guidance on the end of the COVID-19 Public Health Emergency

Image of GettyImages-1318028140.jpg

Key Takeaways

On February 9, the U.S. Department of Health and Human Services (HHS) released new guidance on the agency’s plan to end the federal COVID-19 Public Health Emergency (PHE) declaration on May 11, 2023.

The national PHE declaration was first instated in March 2020 and unlocked flexibilities at the federal and local level that supported efforts to ensure access to critical health services and implement pandemic-related prevention and mitigation strategies during the height of the COVID-19 pandemic.

The guidance released last month will help health care providers, facilities, insurers and other stakeholders including counties to transition beyond the federal PHE declaration, into a long-term strategy for infectious disease mitigation and improved access to and quality of care for patients.

HHS outlined several COVID-19 PHE flexibilities and policies that have already been made permanent or otherwise extended, and those policies that will be expiring when the PHE ends in May. An overview of relevant changes for counties is below.

What will remain?

  • No-cost coverage for vaccinations and certain treatments under most private insurance (out of pocket expenses for some treatments may vary by insurance)
  • No-cost coverage of COVID-19 vaccinations under Medicare Part B and no-cost treatment under Medicare
  • No cost coverage for vaccinations under Medicaid (treatment coverage may vary by state after September 30, 2024)
  • Major Medicare and Medicaid telehealth flexibilities (Medicaid telehealth flexibilities may vary by state)
  • Start date for state eligibility and redeterminations under Medicaid (March 31, 2023)
  • Flexibilities related to access to medication-assisted treatment for opioid use disorder

What will expire?

HHS has also indicated that all COVID-19 products (including tests, vaccines, and treatments) that have been approved by Emergency Use Authorization (EUA) will continue to be authorized for use and accessible to all who need them. Additionally, the agency has committed to providing continued access to pathways for EUAs for other COVID-19 products through the U.S. Food and Drug Administration (FDA).

NACo will continue to monitor federal and local activity in the coming months which will guide counties on the path toward the end of the COVID-19 PHE. As the gateway to our nation’s public health system and a key contributor to the Medicaid program, counties remain committed to ensuring ongoing access to crucial health services for our residents and will continue to serve as frontline providers of COVID-19 related prevention, mitigation and recovery services.

To learn more, view the following federal resources and guidance documents.

Additional Resources

Related News

Abby Winiker, director of Johns Hopkins Bloomberg Overdose Prevention Initiative, highlights ways to stretch opioid dollars. Photo by Charlie Ban
County News

Stretching small opioid settlement allocations helps funding do more

States and localities are set to receive $56 billion in opioid settlement dollars over an 18-year period, but not every county that receives settlement funding will get enough to build out infrastructure.

Medicines in hand
Advocacy

Congress passes SUPPORT Act reauthorization

On September 18, the U.S. Senate passed the SUPPORT for Patients and Communities Reauthorization Act of 2025 (SUPPORT Act Reauthorization) (H.R. 2483) by voice vote, following House passage earlier this year. With strong bipartisan backing in both chambers, the legislation now heads to the President’s desk for signature. 

2234478799
Advocacy

SUPPORT Reauthorization Act of 2025: What it means for counties

On December 1, the bipartisan SUPPORT for Patients and Communities (SUPPORT) Reauthorization Act of 2025  (H.R. 2483) was signed into law. The reauthorization renews vital federal funding for programs that seek to prevent opioid overdoses and expand treatment and recovery options.